On a new tumor marker LyGDI expression in ovarian cancer.docVIP

 PAGE \* MERGEFORMAT 12 On a new tumor marker LyGDI expression in ovarian cancer Study: Male Zhang Zhen Hongying WANG Shu-ling Wu is after [Abstract] Objective To determine the LyGDI is a new marker for ovarian cancer. Methods study population is divided into ovarian cancer, benign ovarian disease and normal groups, ELISA technique to detect the human serum protein levels in the LyGDI and By immunohistochemical expression of chemical technology validation lyGDI. The results of serum lyGDI mean and median levels in ovarian cancer patients as 3.10 mg / L and 2.31 mg / L, significantly higher than in benign ovarian disease population 1.10 mg / L and 0.97 mg / L (P lt;0.05) and normal 1.17 mg / L and 0.55 mg / L (P lt;0.001), benign ovarian disease and normal group the difference was not statistically significant; staining, lyGDI in ovarian cancer highly expressed in benign ovarian tissue did not express. Conclusion lyGDI in ovarian cancer as a new tumor marker. [Keywords:] tumor markers; ovarian cancer; lyGDI [Abstract] Objective To verify if lyGDI is a novel serum biomarker for ovarian carcinoma.MethodsSerum lyGDI was measured by enzyme linked immunosorbent assay for 76 healthy control, 26 patients subsequently diagnosed with ovarian cancer and 12 patients suffered from benign ovarian disease. Intracellular distribution of lyGDI was assessed by immunohistochemistry in benign and malignant ovarian disease. ResultsSerum lyGDI level was significantly elevated among ovarian cancer cases than among benign disease and healthy controls (P lt;0.001). Immunohistochemical analysis demonstrated lyGDI were highly expressed in cancer cells and also found stromal lymphocytes , whereas it is only scattered in stromal lymphocytes in benign ovarian disorders.ConclusionLyGDI may display a novel biomark for screening ovarian cancer. Its distribution in tumor tissue implies it may play an important role in cancinogenesis. [Keywords:] Tumor biomark; Ovarian Cancer; LyG